1. 5,935,821, Aug. 10, 1999, Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma; Malaya Chatterjee, et al., 435/69.6, 69.7, 327, 330; 536/23.4, 23.53 [IMAGE AVAILABLE]

2. 5,290,551, Mar. 1, 1994, Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten; David Berd, 424/193.1, 85.2, 277.1 [IMAGE AVAILABLE]

=> s l2(3a)l4(3a)l1

L9 315 L2(3A)L4(3A)L1

=> d history

(FILE 'USPAT' ENTERED AT 08:20:17 ON 19 AUG 1999)

L1	23901	S	TUMOR OR TUMOUR
L2	380737	S	VACCIN? OR ADMINIST? OR INJECT?
L3	25637	S	HAPTEN OR ANTIGEN OR EPITOPE
L4	544967	S	OWN OR SELF OR PATIENT?
L5	1028	S	L1(10A)L4(10A)L2
L6	464	S	L1(3A)L4(10A)L2
L7	262	S	L1(3A)L4(3A)L2
L8	2	S	L2(A)L4(3A)L1
L9	315	S	L2(3A)L4(3A)L1

09/304859

STN
8/19

L4 ANSWER 1 OF 44 USPATFULL
ACCESSION NUMBER: 1998:147552 USPATFULL
TITLE: Alternative open reading frame DNA of a normal gene and
a novel human cancer antigen encoded therein
INVENTOR(S): Wang, Rong-Fu, Bethesda, MD, United States
Rosenberg, Steven A., Potomac, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Secretary of the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	DATE
PATENT INFORMATION:	US 5840839	19981124
APPLICATION INFO.:	US 1996-599602	19960209 (8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: LeGuyader, John L.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Morgan & Finnegan, L.L.P.
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 14 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 1905
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DETD In another method of **treatment**, **autologous** cytotoxic lymphocytes or **tumor** infiltrating lymphocytes may be obtained from a patient with cancer. The lymphocytes are grown in culture and cancer antigen specific. . .

L4 ANSWER 2 OF 44 USPATFULL
ACCESSION NUMBER: 1998:135159 USPATFULL
TITLE: Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
INVENTOR(S): Wang, Rong-Fu, Bethesda, MD, United States
Rosenberg, Steven A., Potomac, MD, United States
PATENT ASSIGNEE(S): The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

	NUMBER	DATE
PATENT INFORMATION:	US 5831016	19981103
APPLICATION INFO.:	US 1996-725736	19961004 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1996-599602, filed on 9 Feb 1996
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Morgan & Finnegan, L.L.P.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
DRWD In another method of **treatment**, **autologous** cytotoxic lymphocytes or **tumor** infiltrating lymphocytes may be obtained from a patient with cancer. The lymphocytes are grown in culture and cancer antigen specific. . .

L4 ANSWER 3 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 1998193951 EMBASE
TITLE: Alteration of signal-transducing TCRzeta molecules after adoptive immunotherapy.
AUTHOR: Kono K.; Ichihara F.; Iizuka H.; Sekikawa T.; Matsumoto Y.
CORPORATE SOURCE: Dr. K. Kono, First Department of Surgery, Yamanashi Medical University, 1110 Shimogato, Tamaho-machi, Nakakoma-gun, Yamanashi 409-3898, Japan
SOURCE: Biotherapy, (1998) 12/5 (675-676).
Refs: 2
ISSN: 0914-2223 CODEN: BITPE
COUNTRY: Japan
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 016 Cancer
026 Immunology, Serology and Transplantation
037 Drug Literature Index
LANGUAGE: Japanese
SUMMARY LANGUAGE: English; Japanese
AB . . . after adoptive immunotherapy (AIT) using tumor-associated T lymphocytes (TAL). Autologous TAL were cultured in low-dose IL-2 with repeated stimulation of MMC-**treated autologous tumor** cells and then adoptively transferred to patients intravenously or intraperitoneally. TCRzeta expression was restored in 3 of 13 treated patients,. . .

L4 ANSWER 4 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 1998099003 EMBASE
TITLE: The limited effect of adoptive immunotherapy in patients with gastroenterological tumor.
AUTHOR: Kono K.; Ichihara F.; Iizuka H.; Sekikawa T.; Matsumoto Y.
CORPORATE SOURCE: Dr. K. Kono, First Department of Surgery, Yamanashi Medical University, 1110 Shimokato, Tamaho-cho, Nakagoma-gun, Yamanashi 409-38, Japan
SOURCE: Biotherapy, (1998) 12/1 (65-67).
Refs: 1
ISSN: 0914-2223 CODEN: BITPE
COUNTRY: Japan
DOCUMENT TYPE: Journal; Conference Article
FILE SEGMENT: 005 General Pathology and Pathological Anatomy
016 Cancer
026 Immunology, Serology and Transplantation
LANGUAGE: Japanese
SUMMARY LANGUAGE: English; Japanese
AB . . . cancer-specific CTLs from tumor infiltrating lymphocyte (TIL), regional lymph node lymphocyte (RLNL) or tumor associated lymphocyte (TAL) with repeated MMC **treated autologous tumor** stimulation in the presence of rIL-2 (25 IU/ml), and performed the adoptive transfer to the patients with these CTLs. There. . .

L4 ANSWER 5 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 1
ACCESSION NUMBER: 1997:305851 BIOSIS
DOCUMENT NUMBER: PREV199799613654
TITLE: Differences in the recognition of tumor-specific CD8+ T cells derived from solid tumor, metastatic lymph nodes and ascites in patients with gastric cancer.
AUTHOR(S): Kono, Koji (1); Ichihara, Fumiko; Iizuka, Hidehiko; Sekikawa, Takayoshi; Matsumoto, Yoshirou
CORPORATE SOURCE: (1) First Dep. Surg., Yamanashi Med. Univ., 1110 Tamaho, Yamanashi 409-38 Japan
SOURCE: International Journal of Cancer, (1997) Vol. 71, No. 6, pp.
978-981.

ISSN: 0020-7136.
DOCUMENT TYPE: Article
LANGUAGE: English
AB. . . gastric cancer-specific CD8+ T-cell (T-CD8 +) lines derived from different lymphocyte sources in the same patients by repeated stimulation with mitomycin-C-**treated autologous tumor** cells with low-dose interleukin-2, and we compared recognition patterns among the T-CD8 + derived from solid tumor, lymph node metastasis. . .

L4 ANSWER 6 OF 44 USPATFULL
ACCESSION NUMBER: 93:74205 USPATFULL
TITLE: Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen
INVENTOR(S): Fareed, George C., Los Angeles, CA, United States
Sen, Arup, Van Nuys, CA, United States
Ghosh-Dastidar, Pradip, Los Angeles, CA, United States
Jar-How, Lee, Los Angeles, CA, United States
PATENT ASSIGNEE(S): International Genetic Engineering, Inc., Santa Monica, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5242823	19930907
APPLICATION INFO.:	US 1992-956546	19921002 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1990-474730, filed on 16 Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US 1987-131815, filed on 11 Dec 1987, now abandoned And a continuation-in-part of Ser. No. US 1987-97910, filed on 16 Sep 1987, now abandoned which is a continuation-in-part of Ser. No. US 1988-138923, filed on 4 Jan 1988, now abandoned which is a continuation-in-part of Ser. No. US 1986-837494, filed on 7 Mar 1986, now patented, Pat. No. US 4748112
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Nucker, Christine M.
ASSISTANT EXAMINER: Tuscan, Michael
LEGAL REPRESENTATIVE: Marshall, O'Toole, Gerstein, Murray & Borun
NUMBER OF CLAIMS: 8
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 1685
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
SUMM . . . 51, 415-417 (1985); and Wallack et al., Surgery, 96, 791-800 (1984). Active specific immunotherapy may also be attempted by systematically **injecting autologous** (autochthonous) **tumor** cells (i.e., cells derived from the tumor mass of the same patient) intradermally or subcutaneously. Laucius et al., Cancer, 40,. . .

L4 ANSWER 7 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 2
ACCESSION NUMBER: 1993:28698 BIOSIS
DOCUMENT NUMBER: PREV199395016898
TITLE: In vitro proliferation and the cytotoxic specificity of a cryopreserved cytotoxic T cell clone reacting against human autologous tumor cells.
AUTHOR(S): Wada, Yoshimasa; Ikeda, Hideyuki; Ueda, Daisuke; Ohta, Masahiko; Takahashi, Shuji; Hirata, Koichi; Sato, Noriyuki (1); Kikuchi, Kokichi
CORPORATE SOURCE: (1) Dep. Pathol., Sapporo Med. Coll., 060 Sapporo Japan
SOURCE: Journal of Immunological Methods, (1992) Vol. 154, No. 2, pp. 235-243.
ISSN: 0022-1759.
DOCUMENT TYPE: Article

LANGUAGE: English
AB. . . tumor cells in addition to a high concentration (350 U/ml) of rIL-2. Furthermore, these cells were proliferated more efficiently when MMC-**treated autologous tumor** cells were used in vitro as a feeder and an antigenic stimulant. However, such a high dose IL-2 cultivation resulted. . .

L4 ANSWER 8 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 3
ACCESSION NUMBER: 1993:97311 BIOSIS
DOCUMENT NUMBER: PREV199395052507
TITLE: Electron microscopic observation of killer cells induced by mixed culture of lymphocytes with autologous cancer cells and further culture with recombinant interleukin-2.
AUTHOR(S): Murakami, Hiroki (1); Matsuoka, Hiroaki; Fukiage, Tadahiro; Samejima, Yasuhiro; Eura, Masao; Ikawa, Tsutomu; Ishikawa, Takeru; Kanda, Takashi
CORPORATE SOURCE: (1) Dep. Otolaryngol., Kumamoto Univ. Med. Sch., 1-1-1 Honjo, Kumamoto 860 Japan
SOURCE: Auris Nasus Larynx, (1992) Vol. 19, No. 3, pp. 175-188. ISSN: 0385-8146.
DOCUMENT TYPE: Article
LANGUAGE: English
AB Peripheral blood lymphocytes obtained from 2 patients with hypopharyngeal cancer were cultured with mitomycin C **treated autologous tumor** cells (autologous MLTC) for 10 days and further cultured with recombinant interleukin 2 (rIL-2). In one case 10-day MLTC induced. . .

L4 ANSWER 9 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 4
ACCESSION NUMBER: 1991:6907 BIOSIS
DOCUMENT NUMBER: BA91:6907
TITLE: INDUCTION OF KILLER CELLS FROM LYMPHOCYTES IN PLEURAL EFFUSION OF ADVANCED LUNG CANCER PATIENTS.
AUTHOR(S): INOUE Y; SHIJUBO N; UEDE T
CORPORATE SOURCE: DEP. INTERNAL MED., SECT. 3, SAPPORO MED. COLL., S-1, W-16, CHUO-KU, SAPPORO 060, JPN.
SOURCE: JPN J CANCER RES, (1990) 81 (10), 1012-1020. CODEN: JJCREP. ISSN: 0910-5050.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB. . . cells was increased at 2 weeks, but it was remarkably reduced at 4 weeks. When PLEL were stimulated by mitomycin C-**treated autologous tumor** cells during culture, autologous tumor killing activity of PLEL was significantly enhanced even after 4 weeks of cultivation. Cold target. . .

L4 ANSWER 10 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 5
ACCESSION NUMBER: 1991:58023 BIOSIS
DOCUMENT NUMBER: BR40:23378
TITLE: IMMUNOLOGICAL ASPECTS OF MAMMARY TUMORS IN DOGS AND CATS A SURVEY INCLUDING OWN STUDIES AND PERTINENT LITERATURE.
AUTHOR(S): RUTTEN V P M G; MISDORP W; GAUTHIER A; ESTRADA M; MIALOT J P; PARODI A L; RUTTEMAN G R; WEYER K
CORPORATE SOURCE: DEP. INFECT. DIS. IMMUNOL., SECT. IMMUNOL., FAC. VET. MED., UNIV. UTRECHT, P.O. BOX 80.165, 3508 TD UTRECHT, NETH.
SOURCE: Vet. Immunol. Immunopathol., (1990) 26 (3), 211-226. CODEN: VIIMDS. ISSN: 0165-2427.
FILE SEGMENT: BR; OLD
LANGUAGE: English
IT Miscellaneous Descriptors
REVIEW BCG CORYNEBACTERIUM PARVUM VACCINE MITOMYCIN **TREATED**

AUTOLOGOUS TUMOR CELL NEURAMINIDASE **TREATED**
AUTOLOGOUS TUMOR CELL THERAPY

L4 ANSWER 11 OF 44 MEDLINE DUPLICATE 6
ACCESSION NUMBER: 89272025 MEDLINE
DOCUMENT NUMBER: 89272025
TITLE: Basic and clinical study of adoptive immunotherapy using cytotoxic T lymphocyte (CTL) against cancers.
AUTHOR: Kitsukawa K
CORPORATE SOURCE: First Dept. of Internal Medicine, School of Medicine, University of the Ryukyus.
SOURCE: GAN TO KAGAKU RYOHO [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY], (1989 Apr) 16 (4 Pt 2-2) 1448-54. Journal code: 6T8. ISSN: 0385-0684.
PUB. COUNTRY: Japan
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: Japanese
FILE SEGMENT: Priority Journals; Cancer Journals
ENTRY MONTH: 198909
AB . . . Her breast cancer was histologically scirrhous type adenocarcinoma which was resistant to antineoplastics. Patient's PBL were cocultured with mitomycin C **treated-autologous tumor**, and they were proliferated with interleukin 2 or T-cell growth factor (TCGF). Then, these CTL were injected to this patient. .
.

L4 ANSWER 12 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 7
ACCESSION NUMBER: 1989:138475 BIOSIS
DOCUMENT NUMBER: BA87:73128
TITLE: CONTROLLED CLINICAL TRIAL OF ADJUVANT IMMUNOTHERAPY WITH BCG AND NEURAMINIDASE-**TREATED AUTOLOGOUS TUMOR** CELLS IN LARGE BOWEL CANCER.
AUTHOR(S): GRAY B N; WALKER C; ANDREWARTHA L; FREEMAN S; BENNETT R C
CORPORATE SOURCE: UNIV. DEP. SURG., ROYAL PERTH HOSP., WELLINGTON ST., PERTH,
WESTERN AUSTRALIA 6000, AUST.
SOURCE: J SURG ONCOL, (1989) 40 (1), 34-37.
CODEN: JSONAU. ISSN: 0022-4790.
FILE SEGMENT: BA; OLD
LANGUAGE: English
TI CONTROLLED CLINICAL TRIAL OF ADJUVANT IMMUNOTHERAPY WITH BCG AND NEURAMINIDASE-**TREATED AUTOLOGOUS TUMOR** CELLS IN LARGE BOWEL CANCER.

L4 ANSWER 13 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 8
ACCESSION NUMBER: 1989:52909 BIOSIS
DOCUMENT NUMBER: BA87:28909
TITLE: MELBOURNE AUSTRALIA TRIAL OF ADJUVANT IMMUNOTHERAPY IN OPERABLE LARGE BOWEL CANCER.
AUTHOR(S): GRAY B N; WALKER C; ANDREWARTHA L; FREEMAN S; BENNETT R C
CORPORATE SOURCE: UNIV. DEP. SURG., ROYAL PERTH HOSP., WELLINGTON ST., PERTH,
WA 6000, AUST.
SOURCE: AUST N Z J SURG, (1988) 58 (1), 43-46.
CODEN: ANZJA7. ISSN: 0004-8682.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB. . . Stage B or C large bowel cancer. The immunotherapy consisted of a 2 year programme of vaccinations with BCG and neuraminidase-**treated autologous tumour** cells. Three hundred and one patients entered the trial. At 5 years of follow-up there is no evidence that this.
. .

L4 ANSWER 14 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 9
ACCESSION NUMBER: 1987:169753 BIOSIS

DOCUMENT NUMBER: B[redacted]:88194
TITLE: T[redacted]R THERAPY OF NEOPLASTIC DISEAS[redacted]WITH TUMOR CELLS AND NEURAMINIDASE FURTHER EXPERIMENTAL STUDIES ON CHESSBOARD VACCINATION IN CANINE MAMMARY TUMORS.
AUTHOR(S): SEDLACEK H H; HAGMAYER G; SEILER F R
CORPORATE SOURCE: RES. LAB. OF BEHRINGWERKE AG, D-3550 MARBURG, FRG.
SOURCE: CANCER IMMUNOL IMMUNOTHER, (1986 (RECD 1987)) 23 (3), 192-199.
CODEN: CIIMDN. ISSN: 0340-7004.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB. . . was investigated. The i. d. injections were performed in a chessboard-like manner: different numbers (105, 106, 107, and 108) of mitomycin-**treated autologous tumor** cells (M-TC) were each mixed with different amounts (10, 50, and 100 mU) of VCN.
These different mixtures were injected. . .

L4 ANSWER 15 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.DUPLICATE 10
ACCESSION NUMBER: 85164706 EMBASE
DOCUMENT NUMBER: 1985164706
TITLE: Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.
AUTHOR: Wood S.M.; Kraenzlin M.E.; Adrian T.E.; Bloom S.R.
CORPORATE SOURCE: Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 0HS, United Kingdom
SOURCE: Gut, (1985) 26/5 (438-444).
CODEN: GUTTAK
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
048 Gastroenterology
030 Pharmacology
003 Endocrinology
016 Cancer
006 Internal Medicine
LANGUAGE: English
AB . . . for seven months with this analogue which has controlled his previously life threatening diarrhoea caused by a malignant VIP secreting **tumour**. He gives his **own injection** twice daily, and has returned to a full and active life. This is a promising agent both for acute treatment. . .

L4 ANSWER 16 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 11
ACCESSION NUMBER: 1985:234890 BIOSIS
DOCUMENT NUMBER: BA79:14886
TITLE: COMBINATION CHEMOIMMUNOTHERAPY FOR ADVANCED GASTRIC CARCINOMA.
AUTHOR(S): AKIYOSHI T; KAWAGUCHI M; ARINAGA S; MIYAZAKI S; KOBA F; WADA T; TSUJI H
CORPORATE SOURCE: DEP. OF SURGERY, MED. INST. OF BIOREGULATION, KYUSHU UNIV.,
4546 TSURUMIBARU, BEPPU 874, JAPAN.
SOURCE: JPN J SURG, (1984) 14 (3), 185-190.
CODEN: JJSGAY. ISSN: 0047-1909.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB. . . advanced gastric carcinoma were treated with a combination chemo-immunotherapy regimen that consisted of active immunotherapy with Vibrio cholarae neuraminidase (VCN) **treated autologous tumor** cells admixed with BCG and drugs including cyclophosphamide, mitomycin C (MMC) and 5-fluorouracil, followed by long term tegafur (FT) and. . .

L4 ANSWER 17 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 12

ACCESSION NUMBER: 1[redacted]340730 BIOSIS
DOCUMENT NUMBER: BA[redacted]:77210
TITLE: A TRIAL OF ADJUVANT COMBINATION CHEMO IMMUNO THERAPY FOR STAGE III CARCINOMA OF STOMACH.
AUTHOR(S): AKIYOSHI T; KAWAGUCHI M; ARINAGA S; MIYAZAKI S; KOBA F; WADA T; TSUJI H
CORPORATE SOURCE: DEP. OF SURGERY, MED. INSTITUTE OF BIOREGULATION, KYUSHU UNIV., BEPPU, 874 JAPAN.
SOURCE: J SURG ONCOL, (1984) 26 (2), 86-90.
CODEN: JSONAU. ISSN: 0022-4790.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB. . . with stage III carcinoma of stomach, following curative resection. The treatment regimen consisted of active immunotherapy with Vibrio cholerae neuraminidase (VCN)-**treated autologous** **tumor** cells admixed with BCG and chemotherapy with drugs such as cyclophosphamide (CY), mitomycin C (MMC) and 5-fluorouracil (FU), which proved. . .
IT Miscellaneous Descriptors
HUMAN VIBRIO-CHOLERAE NEURAMINIDASE **TREATED** **AUTOLOGOUS TUMOR** CELLS BCG IMMUNOLOGIC-DRUG CYCLO PHOSPHAMIDE MITOMYCIN C 5 FLUORO URACIL TEGAFUR ANTINEOPLASTIC-DRUG SURGERY PROGNOSIS

L4 ANSWER 18 OF 44 SCISEARCH COPYRIGHT 1999 ISI (R)
ACCESSION NUMBER: 83:598555 SCISEARCH
THE GENUINE ARTICLE: RR228
TITLE: IMMUNOTHERAPEUTIC APPROACH OF METASTATIC KIDNEY CANCER USING IMMUNE-RNA (I-RNA) FROM GUINEA-PIGS IMMUNIZED WITH FORMALIN **TREATED AUTOLOGOUS** **TUMOR**-CELLS (TC)
AUTHOR: CORRADO F (Reprint); PIZZA G; MARTINELLI A
CORPORATE SOURCE: OSPED M MALPIGHI, DIV UROL 1, I-40139 BOLOGNA, ITALY
COUNTRY OF AUTHOR: ITALY
SOURCE: PROSTATE, (1983) Vol. 4, No. 6, pp. 660.
DOCUMENT TYPE: Conference; Journal
FILE SEGMENT: LIFE
LANGUAGE: ENGLISH
REFERENCE COUNT: No References
TI IMMUNOTHERAPEUTIC APPROACH OF METASTATIC KIDNEY CANCER USING IMMUNE-RNA (I-RNA) FROM GUINEA-PIGS IMMUNIZED WITH FORMALIN **TREATED** **AUTOLOGOUS TUMOR**-CELLS (TC)

L4 ANSWER 19 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 13
ACCESSION NUMBER: 1983:285245 BIOSIS
DOCUMENT NUMBER: BA76:42737
TITLE: INDUCTION OF DELAYED HYPER SENSITIVITY REACTIONS IN CANCER PATIENTS BY CHOLESTEROL HEMI SUCCINATE **TREATED** **AUTOLOGOUS TUMOR** CELLS.
AUTHOR(S): SKORNICK Y; DRESDALE A R; SINDELAR W F
CORPORATE SOURCE: BUILDING 10, ROOM 10N206, NATIONAL INST. HEALTH, BETHESDA, MD. 20205.
SOURCE: J NATL CANCER INST, (1983) 70 (3), 465-468.
CODEN: JNCIAM. ISSN: 0027-8874.
FILE SEGMENT: BA; OLD
LANGUAGE: English
TI INDUCTION OF DELAYED HYPER SENSITIVITY REACTIONS IN CANCER PATIENTS BY CHOLESTEROL HEMI SUCCINATE **TREATED AUTOLOGOUS** **TUMOR** CELLS.
AB. . . malignant tumors. Patients were given intradermal injections of 106 autologous, irradiated, CHS-treated tumor cells. Control injections consisted of untreated irradiated **tumor** cells, CHS-**treated autologous** normal peripheral lymphocytes, strongly positive skin reactions were observed when CHS-treated tumor cells were used. Untreated irradiated cells gave negative. . .

L4 ANSWER 20 OF 44 PLUS COPYRIGHT 1999 ACS
ACCESSION NUMBER: 1983:606601 CAPLUS
DOCUMENT NUMBER: 99:206601
TITLE: Vaginal administration of a potent luteinizing hormone-releasing hormone analog (leuprolide)
AUTHOR(S): Okada, Hiroaki
CORPORATE SOURCE: Cent. Res. Div., Takeda Chem. Ind., Ltd., Osaka, 532, Japan
SOURCE: Takeda Kenkyushoho (1983), 42(1/2), 150-208
CODEN: TAKHAA; ISSN: 0371-5167
DOCUMENT TYPE: Journal
LANGUAGE: Japanese
AB A rational dosage method for leuprolide (I) [53714-56-0] **self-administration** in mammary **tumor** therapy was studied in rats by detg. the ovulation-inducing activity and RIA of serum levels of I
and gonadotropin after. . .

L4 ANSWER 21 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 14
ACCESSION NUMBER: 1982:173435 BIOSIS
DOCUMENT NUMBER: BA73:33419
TITLE: SEQUENTIAL COMBINATION CHEMO IMMUNO THERAPY FOR VARIOUS MALIGNANT TUMORS CLINICAL AND LABORATORY RESULTS.
AUTHOR(S): AKIYOSHI T; KAWAGUCHI M; MIYAZAKI S; KOBA F; TSUJI H
CORPORATE SOURCE: DEP. SURG., RES. INST. BALNEOTHER., KYUSHU UNIV., BEPPU 874, JPN.
SOURCE: JPN J SURG, (1981) 11 (4), 283-290.
CODEN: JJSGAY. ISSN: 0047-1909.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB. . . advanced malignant tumors. The treatment regimen consisted of cyclophosphamide (CY) 200 mg i.v. on day 1, Vibrio cholerae neuraminidase (VCN) **treated autologous tumor** cells admixed with BCG 5-10 mg intradermally on day 4 and mitomycin C (MMC) 10-16 mg and
5-fluorouracil (FU) 500. . . .

L4 ANSWER 22 OF 44 CANCERLIT
ACCESSION NUMBER: 81621250 CANCERLIT
DOCUMENT NUMBER: 81621250
TITLE: SEQUENTIAL COMBINATION CHEMOIMMUNOTHERAPY FOR MALIGNANT DISEASE. II. CLINICAL AND LABORATORY RESULTS.
AUTHOR: Akiyoshi T; Kawaguchi M; Miyazaki S; Koba F; Tsuji H
CORPORATE SOURCE: Dept. Surgery, Res. Inst. Balneotherapeutics, Kyushu Univ.,
Beppu-shi, Oita Pref. 874, Japan.
SOURCE: Gan To Kagaku Ryoho, (1980). Vol. 7, No. 11, pp. 2019-2026.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: ICDB; L
LANGUAGE: Japanese
ENTRY MONTH: 198108
AB . . . patients with various advanced malignant tumors. The treatment program consisted of cyclophosphamide 200 mg iv on day 1, Vibrio cholerae neuraminidase-**treated autologous tumor** cells admixed with BCG 5 to 10 mg id on day 4 and mitomycin C 10 to 16 mg and. . .

L4 ANSWER 23 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 15
ACCESSION NUMBER: 1980:204575 BIOSIS
DOCUMENT NUMBER: BA69:79571
TITLE: TRANSITIONAL CELL CARCINOMA OF THE BLADDER DIFFERENCES BETWEEN PRIMARY TUMOR AND FOLLOWING RELAPSES.
AUTHOR(S): PIZZA G; VIZA D; FINI M; CUZZOCREA D; MENNITI D; CORRADO F
CORPORATE SOURCE: DIV. UROL., OSP. M. MALPIGHI, VIA P. PALAGI 9, BOLOGNA, ITALY.

SOURCE: EUROL, (1980) 6 (1), 45-47.
CODEN: EUURAV. ISSN: 0302-2838.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB The presence of tumor-associated antigens in bladder carcinomas was shown in leukocyte migration inhibition and lymphocyte stimulation using formalin-**treated autologous tumor** cells as antigen. The treatment of patients with an in vitro-produced specific transfer factor enhances their reactivity in these tests.. . .

L4 ANSWER 24 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 16
ACCESSION NUMBER: 1980:163653 BIOSIS
DOCUMENT NUMBER: BA69:38649
TITLE: TUMOR METASTASES AND CELL MEDIATED IMMUNITY IN A MODEL SYSTEM IN DBA-2 MICE 6. SIMILAR SPECIFICITY PATTERNS OF PROTECTIVE ANTI TUMOR IMMUNITY IN-VIVO AND CYTOLYTIC THYMUS DERIVED CELLS IN-VITRO.
AUTHOR(S): BOSSLET K; SCHIRRMACHER V; SHANTZ G
CORPORATE SOURCE: INST. IMMUNOL. GENET., DTSCH. KREBSFORSCHUNGSZENT., HEIDELBERG, W. GER.
SOURCE: INT J CANCER, (1979) 24 (3), 303-313.
CODEN: IJCNAW. ISSN: 0020-7136.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB. . . lymphocytes (CTL) were obtained after sensitization in vivo with viable tumor cells and restimulation in vitro for 4-5 days with mitomycin-C-**treated autologous tumor** cells. Anti-Eb and anti-ESb CTL showed high cytolytic activity in a 4-h 51Cr release assay against the autologous tumor lines.. . .

L4 ANSWER 25 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V. DUPLICATE 17
ACCESSION NUMBER: 79249432 EMBASE
DOCUMENT NUMBER: 1979249432
TITLE: Immunotherapy of spontaneous mammary tumors in mongrel dogs with autologous tumor cells and neuraminidase.
AUTHOR: Sedlacek H.H.; Weise M.; Lemmer A.; Seiler F.R.
CORPORATE SOURCE: Res. Lab. Behringwerke AG, 3550 Marburg/Lahn, Germany
SOURCE: Cancer Immunology Immunotherapy, (1979) 6/1 (47-58).
CODEN: CIIMDN
COUNTRY: Germany
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
016 Cancer
026 Immunology, Serology and Transplantation
LANGUAGE: English
AB . . . blindly distributed into six groups in three consecutive studies.
The results show that the therapeutic effect of the injection of VCN-**treated autologous tumor** cells depends on the number of tumor cells injected: injection of 2x107 tumor cells repeatedly induced regression of the residual. . .

L4 ANSWER 26 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 79042556 EMBASE
DOCUMENT NUMBER: 1979042556
TITLE: Spontaneous mammary tumors in mongrel dogs. A relevant model to demonstrate tumor therapeutical success by application of neuraminidase-treated tumor cells.
AUTHOR: Sedlacek H.H.; Seiler F.R.
CORPORATE SOURCE: Behringwerke AG, D-3550 Marburg/Lahn, Germany
SOURCE: Developments in Biological Standardization, (1978) VOL. 38/- (399-412).
CODEN: DVBSA3
COUNTRY: Switzerland

DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
026 Immunology, Serology and Transplantation
016 Cancer
010 Obstetrics and Gynecology
004 Microbiology
LANGUAGE: English
AB . . . certain time intervals. The results after a follow-up examination
period of about three years show that the tumor-therapeutical effect of VCN-**treated autologous tumor** cells depends
on the number of tumor cells injected: 2 x 107 tumor cells induce long lasting tumor regression, prolongation. . .

L4 ANSWER 27 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 79042555 EMBASE
DOCUMENT NUMBER: 1979042555
TITLE: Possible immunological action of Vibrio cholerae neuraminidase (VCN) in tumor immunotherapy.
AUTHOR: Sedlacek H.H.; Johannsen R.; Seiler F.R.
CORPORATE SOURCE: Behringwerke AG, D-3550 Marburg/Lahn, Germany
SOURCE: Developments in Biological Standardization, (1978) VOL. 38/- (387-398).
CODEN: DVBSA3
COUNTRY: Switzerland
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
016 Cancer
026 Immunology, Serology and Transplantation
004 Microbiology
LANGUAGE: English
AB From literature it is known that the injection of VCN-**treated autologous tumor** cells into **tumor**-bearing mice immunologically induced tumor regression. The increase of immunogenicity of such treated cells has been said to be contributed to. . .

L4 ANSWER 28 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS DUPLICATE 18
ACCESSION NUMBER: 1979:162604 BIOSIS
DOCUMENT NUMBER: BA67:42604
TITLE: DEMONSTRATION OF SPECIFIC CELL MEDIATED ANTI TUMOR IMMUNITY
IN LUNG CANCER TO AUTOLOGOUS TISSUE EXTRACTS.
AUTHOR(S): DEAN J H; JERRELLS T R; CANNON G B; KIBRITE A; BAUMGARDNER B; WEESE J L; SILVA J; HERBERMAN R B
CORPORATE SOURCE: BIOMED. RES. DIV., DEP. IMMUNOL., LITTON BIONETICS INC. 5516 NICHOLSON LANE, KENSINGTON, MD. 20795, USA.
SOURCE: INT J CANCER, (1978) 22 (4), 367-377.
CODEN: IJCNAW. ISSN: 0020-7136.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB. . . interactions as measured in a microculture (200 .mu.l) lymphocyte proliferation (LP) assay. Positive lymphoproliferative responses were observed with cryopreserved intact mitomycin-C-**treated autologous tumor** cells (8/12 or 67% patients reactive) and with hypotonic membrane extracts (HMP) of tumor cells (28/40 or 70%). Good correlation. . .

L4 ANSWER 29 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.DUPLICATE 19
ACCESSION NUMBER: 79142220 EMBASE
DOCUMENT NUMBER: 1979142220
TITLE: Specificity of cell membrane antigens in prostate cancer.
AUTHOR: Brannen G.E.; Coffey D.S.
CORPORATE SOURCE: Madigan Army Med. Cent., Tacoma, Wash. 98431, United States
SOURCE: National Cancer Institute Monograph, (1978) Monogr. 49/- (251-253).

C[redacted]N: NCIMAV
COUNTRY: United States
DOCUMENT TYPE: Journal
FILE SEGMENT: 016 Cancer
026 Immunology, Serology and Transplantation
020 Gerontology and Geriatrics
028 Urology and Nephrology
LANGUAGE: English
AB . . . given intradermal injections of soluble tumor antigens extracted from their tumors, exhibited a cutaneous, delayed type hypersensitivity response to the **injected autologous tumor** extracts. No positive reactions were observed in response to solubilized components of control tissues, including BPH. These observations suggest that. . .

L4 ANSWER 30 OF 44 CANCERLIT
ACCESSION NUMBER: 78804857 CANCERLIT
DOCUMENT NUMBER: 78804857
TITLE: ACTIVE SPECIFIC IMMUNOTHERAPY OF ADVANCED RENAL-CELL CARCINOMA.
AUTHOR: Tykka H; Oravisto K J; Lehtonen T; Sarna S; Tallberg T
CORPORATE SOURCE: Lab. Immunology, Helsinki Univ. Central Hosp., Haartmaninkatu 3, 00290 Helsinki 29, Finland.
SOURCE: Eur Urol, (1978). Vol. 4, No. 4, pp. 250-258.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: CATH; L
LANGUAGE: English
ENTRY MONTH: 197811
AB . . . old) with advanced adenocarcinoma of the kidney (Stage III-IV, Grade I-III). None had brain metastases. Postoperative immunotherapy (ImT) with ethyl chloroformate-**treated autologous tumor** vaccine and an individually selected antigen (Candida albicans or tuberculin-purified protein derivative) was given id (av, 1x/mo until the material. . .

L4 ANSWER 31 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 78158636 EMBASE
DOCUMENT NUMBER: 1978158636
TITLE: Effect of vibrio cholerae neuraminidase (VCN) **treated autologous tumor** cells on the growth of the spontaneous mammary tumor in dogs.
AUTHOR: Sedlacek H.H.; Weise M.; Meesmann H.; Seiler F.R.
CORPORATE SOURCE: Behringw. AG, Marburg/Lahn, Germany
SOURCE: Allergologia et Immunopathologia, (1977) 5/4 (383-384). CODEN: AGIMBJ
COUNTRY: Spain
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
LANGUAGE: English
TI Effect of vibrio cholerae neuraminidase (VCN) **treated autologous tumor** cells on the growth of the spontaneous mammary tumor in dogs.

L4 ANSWER 32 OF 44 CANCERLIT
ACCESSION NUMBER: 77807757 CANCERLIT
DOCUMENT NUMBER: 77807757
TITLE: NEURAMINIDASE AND TUMOR IMMUNOTHERAPY.
AUTHOR: Sedlacek H H; Seiler F R; Schwick H G
CORPORATE SOURCE: Bahringwerke AG, D-3550 Marburg/Lahn, W. Germany.
SOURCE: Klin Wochenschr, (1977). Vol. 55, No. 5, pp. 199-214. ISSN: 0023-2173.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: CATH; L
LANGUAGE: English
ENTRY MONTH: 197709

AB . . . immunot[redacted]apy are presented. Among recur[redacted]t and metastatic melanoma patients who survived long enough to rece[redacted]e sc injections of irradiated V cholerae-**treated autologous tumor** cells and BCG during the last phase of a 4-phase immunotherapy program, 6 showed complete regression over periods of 6-30. . .

L4 ANSWER 33 OF 44 CANCERLIT
ACCESSION NUMBER: 77806132 CANCERLIT
DOCUMENT NUMBER: 77806132
TITLE: ABNORMALITIES OF MONOCYTE CHEMOTAXIS IN PATIENTS WITH MELANOMA: EFFECTS OF IMMUNOTHERAPY AND TUMOR REMOVAL.
AUTHOR: Snyderman R; Seigler H F; Meadows L
CORPORATE SOURCE: Box 3892, Duke Univ. Medical Center, Durham, NC 27710.
SOURCE: J Natl Cancer Inst, (1977). Vol. 58, No. 1, pp. 37-44. ISSN: 0027-8874.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: CATH; L
LANGUAGE: English
ENTRY MONTH: 197707
AB . . . cells, then readministering these cells iv (Phase III). Patients were challenged 30 days later with an sc inoculum of irradiated neuraminidase-**treated autologous tumor** cells plus BCG (Phase IV). After immunotherapy or surgical removal of the neoplasm, the number of MCR-depressed patients dropped from. . .

L4 ANSWER 34 OF 44 CANCERLIT
ACCESSION NUMBER: 76800139 CANCERLIT
DOCUMENT NUMBER: 76800139
TITLE: CYTOTOXICITY REACTIONS DURING IMMUNOTHERAPY OF MELANOMA WITH NEURAMINIDASE ALTERED AUTOLOGOUS TUMOR CELLS.
AUTHOR: Miller E E; Rosato F E; Brown A S; Moskovitz A; Johnson J
CORPORATE SOURCE: Harrison Dept. Surgical Res., Univ. Pennsylvania Sch. Medicine, Philadelphia, PA.
SOURCE: J Surg Oncol, (1976). Vol. 8, No. 1, pp. 31-34. ISSN: 0022-4790.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: CATH; L
LANGUAGE: English
ENTRY MONTH: 197611
AB . . . patterns of changing serum cytotoxicity and serum blocking effect suggested the phenomena may be related, and that active immunotherapy with neuraminidase-**treated autologous tumor** cells may play a role in the unblocking of serum blocking effect and prevention of metastases. (12 refs)

L4 ANSWER 35 OF 44 CANCERLIT
ACCESSION NUMBER: 77607436 CANCERLIT
DOCUMENT NUMBER: 77607436
TITLE: REGRESSION OF SPONTANEOUS MAMMARY TUMORS IN DOGS AFTER INJECTION OF VIBRIO CHOLERAE NEURAMINIDASE (VCN)-TREATED TUMOR CELLS.
AUTHOR: Sedlacek H H; Meesmann H; Seiler F R
CORPORATE SOURCE: Berring Institute, 355 Marburg(Lahn), FRG.
SOURCE: Proc Am Assoc Cancer Res, (1975). Vol. 16, pp. 141. ISSN: 0569-2261.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: ICDB; L
LANGUAGE: English
ENTRY MONTH: 197704
AB . . . min/37 degrees C). Group 1 received twice 1 x 10**7; Group 2 was injected twice with 5 x 10**7 likewise **treated autologous tumor** cells sc in the neck on the day of operation and on the next day. The control group was equally. . .

L4 ANSWER 36 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.DUPLICATE 20
ACCESSION NUMBER: 76002176 EMBASE
DOCUMENT NUMBER: 1976002176
TITLE: Specificity of cell membrane antigens in prostatic cancer.
AUTHOR: Brannen G.E.; Gomolka D.M.; Coffey D.S.
CORPORATE SOURCE: James Buchanan Brady Urol. Inst., Johns Hopkins Hosp., Baltimore, Md., United States
SOURCE: CANCER CHEMOTHER.REP., (1975) 59/1 (127-138).
CODEN: CNCRA6
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
016 Cancer
026 Immunology, Serology and Transplantation
028 Urology and Nephrology
LANGUAGE: English
AB . . . antigens extracted from their own tumors. Three of the seven patients exhibited a cutaneous delayed type hypersensitivity response to the **injected autologous tumor** extracts. No positive reactions were observed in response to solubilized components of control tissues, including benign prostatic hyperplasia. The significance.
. .

L4 ANSWER 37 OF 44 TOXLINE
ACCESSION NUMBER: 1995:63643 TOXLINE
DOCUMENT NUMBER: IPA-75-146077
TITLE: Positive antiglobulin test after BCG immunotherapy.
COMMENT: Letters
AUTHOR: Coller B S; Lundberg W B; Albright L; Ommaya A K; Gralnick H R
CORPORATE SOURCE: National Institutes of Health, Bethesda, Maryland 20014.
SOURCE: N. Engl. J. Med, (1974). Vol. 291, Aug 29, pp. 474 (REF).
CODEN: NEJMAG. ISSN: 0028-4793.
FILE SEGMENT: IPA
LANGUAGE: English
OTHER SOURCE: IPA 12-146077
ENTRY MONTH: 199507
AB . . . direct (and later indirect) antiglobulin test developed after 8 months of the following antitumor therapy: biweekly S.C. injections of neuramidinase **treated autologous tumor** cells; monthly intradermal BCG and intratumoral purified protein derivative of tuberculin (via a reservoir); systemic lomustine (CCNU); and intratumoral 8-azaguanine.

L4 ANSWER 38 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 76112239 EMBASE
DOCUMENT NUMBER: 1976112239
TITLE: Regression of spontaneous mammary tumors of dogs after injection of neuraminidase treated tumor cells: a preliminary communication.
AUTHOR: Sedlacek H.H.; Meesmann H.; Seiler F.R.
CORPORATE SOURCE: Behring Inst., Marburg, Germany
SOURCE: BEHRING INST.MITT., (1974) No.55/- (349-355).
CODEN: XXXXXB
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
005 General Pathology and Pathological Anatomy
026 Immunology, Serology and Transplantation
016 Cancer
LANGUAGE: English
AB . . . and subsequently with highly purified VCN (100 U/ml/5 x 107 cells/30 min/37.degree. C). Twelve dogs received 1 x 107 likewise **treated autologous tumor** cells s.c. in the neck on the day of operation and on the day thereafter. Clinical

investigations o[redacted]e remaining. . .

L4 ANSWER 39 OF 44 BIOSIS COPYRIGHT 1999 BIOSIS
ACCESSION NUMBER: 1974:73363 BIOSIS
DOCUMENT NUMBER: BR10:73363
TITLE: VIBRIO-CHOLERAE NEURAMINIDASE **TREATED AUTOLOGOUS TUMOR** CELLS AS IMMUNO THERAPY IN HUMAN TUMORS.
AUTHOR(S): ROSATO F E; MILLER E; ROSATO E F; MULLIS W; JOHNSON J; BROWN A
SOURCE: Proc. Am. Assoc. Cancer Res., (1974) 15, 159. CODEN: PAACA3. ISSN: 0569-2296.
DOCUMENT TYPE: Conference
FILE SEGMENT: BR; OLD
LANGUAGE: Unavailable
TI VIBRIO-CHOLERAE NEURAMINIDASE **TREATED AUTOLOGOUS TUMOR** CELLS AS IMMUNO THERAPY IN HUMAN TUMORS.

L4 ANSWER 40 OF 44 SCISEARCH COPYRIGHT 1999 ISI (R)
ACCESSION NUMBER: 74:116289 SCISEARCH
THE GENUINE ARTICLE: S2695
TITLE: VIBRIO CHOLERA NEURAMINIDASE (VCN) **TREATED AUTOLOGOUS TUMOR**-CELLS AS IMMUNOTHERAPY IN HUMAN TUMORS
AUTHOR: ROSATO F E (Reprint); MILLER E; ROSATO E F; MULLIS W; JOHNSON J; BROWN A
CORPORATE SOURCE: UNIV PENN, DEPT SURG, 3400 SPRUCE ST, PHILADELPHIA, PA, 19104
COUNTRY OF AUTHOR: USA
SOURCE: PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, (1974) Vol. 15, No. MAR, pp. 159.
DOCUMENT TYPE: Conference; Journal
LANGUAGE: ENGLISH
REFERENCE COUNT: No References
TI VIBRIO CHOLERA NEURAMINIDASE (VCN) **TREATED AUTOLOGOUS TUMOR**-CELLS AS IMMUNOTHERAPY IN HUMAN TUMORS

L4 ANSWER 41 OF 44 CANCERLIT
ACCESSION NUMBER: 74706277 CANCERLIT
DOCUMENT NUMBER: 74706277
TITLE: IMMUNOLOGICAL STUDIES IN ACUTE LEUKEMIA.
AUTHOR: Santos G W; Mullins G M; Bias W B; Anderson P N; Graziano K D; Klein D L; Burke P J
CORPORATE SOURCE: Dept. Med., Johns Hopkins Univ., Baltimore, Md.
SOURCE: Recent Results Cancer Res, (1974). Vol. 47, pp. 17-24. ISSN: 0080-0015.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: CARC; L
LANGUAGE: English
ENTRY MONTH: 197512
AB . . . unresponsive to the antigens tested in the skin tests but in no instance was a delayed hypersensitivity response to intradermally **injected autologous tumor** cells found. Nine normal siblings were found to be HL-A identical to their leukemic siblings and eight of these responded. . .

L4 ANSWER 42 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.DUPLICATE 21
ACCESSION NUMBER: 75062773 EMBASE
DOCUMENT NUMBER: 1975062773
TITLE: Vibrio cholera neuraminidase (VCN) **treated autologous tumor** cells as immunotherapy in human tumors.
AUTHOR: Rosato F.E.; Miller E.; Mullis W.; et al.
CORPORATE SOURCE: Dept. Surg., Univ. Pennsylvania, Philadelphia, Pa. 19104,

United States
SOURCE: European Surgical Research, (1974) 6/sup 1 (13).
CODEN: EUSRBM
DOCUMENT TYPE: Journal
FILE SEGMENT: 037 Drug Literature Index
LANGUAGE: English
TI Vibrio cholera neuraminidase (VCN) **treated autologous tumor** cells as immunotherapy in human tumors.

L4 ANSWER 43 OF 44 EMBASE COPYRIGHT 1999 ELSEVIER SCI. B.V.
ACCESSION NUMBER: 75100801 EMBASE
DOCUMENT NUMBER: 1975100801
TITLE: Vibrio cholera neuraminidase (VCN) **treated autologous tumor** cells as immunotherapy in human tumors.
AUTHOR: Rosato F.E.; Miller E.; Rosato E.F.; et al.
CORPORATE SOURCE: Dept. Surg., Univ. Pennsylvania, Philadelphia, Pa. 19104, United States
SOURCE: Proceedings of the American Association for Cancer Research, (1974) Vol. 15 No. 703/-.
CODEN: PAACA3
DOCUMENT TYPE: Journal
LANGUAGE: English
TI Vibrio cholera neuraminidase (VCN) **treated autologous tumor** cells as immunotherapy in human tumors.

L4 ANSWER 44 OF 44 CANCERLIT
ACCESSION NUMBER: 71700940 CANCERLIT
DOCUMENT NUMBER: 71700940
TITLE: EFFECT OF INOCULA OF BENZO[A]PYRENE-TREATED SARCOMA CELLS ON GROWTH OF PRIMARY TUMORS IN RATS.
AUTHOR: Hall J G; Glover D J
CORPORATE SOURCE: Chester Beatty Res. Inst., Sutton, Surrey, England.
SOURCE: J Natl Cancer Inst, (1970). Vol. 45, No. 6, pp. 1163-1168.
ISSN: 0027-8874.
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
FILE SEGMENT: CARC; L
LANGUAGE: English
ENTRY MONTH: 197512
AB . . . not act by increasing the strength of the tumor-specific antigen,
for inocula of carcinogen-allogenic treated tumor cells and inocula of carcinogen-**treated autologous tumor** cells
had almost the same efficacy in tumor growth retardation.

FILE 'BIOSIS, EMBASE, MEDLINE, CAPLUS, APIPAT, CROPU, DGENE, DPCI, EUROPATFULL, IFIPAT, INPADOC, JAPIO, PAPERCHEM2, PATDD, PATDPA, PATOSDE, PATOSEP, PATOSWO, PIRA, RAPRA, TULSA, TULSA2, USPATFULL, LIFESCI, TOXLINE, CANCERLIT, SCISEARCH' ENTERED AT 13:37:20 ON 19 AUG 1999

L1 39791 S (ADMINIST? OR INJECT? OR TREAT?)(A)(PATEINT? OR OWN OR SELF
O

L2 3022524 S TUMOR? OR TUMOUR?

L3 103 S L1(3A)L2

L4 44 DUP REM L3 (59 DUPLICATES REMOVED)